Keio Cardiovascular Study on Pathogenesis of Anticancer Drugs Contributing to Cardiovascular Events

Keio Cardiovascular Study on Pathogenesis of Anticancer Drugs Contributing to Cardiovascular Events - Keio Onco-Cardiomics Study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000033773

Enrollment

5000

Registered

2018-09-01

Start date

2018-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Scheduled or received chemotharapy for tumors of hematopoietic and lymphoid tissue, lung, digestive tract, liver, pancreas, gallbladder and biliary tract, breast, genital and urinary tract, and skin 2. Expected to survive for more than 6 months 3. Provided informed consent

Exclusion criteria

Exclusion criteria: ineligible for the study as judged by the investigator

Design outcomes

Primary

Measure	Time frame
1. Frequencies and types of cardiovascular events 2. Investigation of factors associated with the onset of cardiovascular events and clarification of pathogensis of anticancer therapies contributing to cardiovascular damages	—

Secondary

Measure	Time frame
Changes in 1)biomarkers; 2)imagings; and 3)exercise tolerance before and after chemotherapy to treat cancer	—

Countries

Japan

Contacts

Public ContactYasuyuki Shiraishi

Keio University School of Medicine Cardiology

yasshiraishi@keio.jp0333531211

Outcome results